Adage Capital Partners Gp, L.L.C. Dyne Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,191,000 shares of DYN stock, worth $41 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
3,191,000Holding current value
$41 Million% of portfolio
0.05%Shares
14 transactions
Others Institutions Holding DYN
# of Institutions
211Shares Held
122MCall Options Held
36.5KPut Options Held
74.3K-
Ra Capital Management, L.P. Boston, MA9.71MShares$125 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$121 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$117 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$98.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$95 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $666M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...